VGH-TAYLOR: Comprehensive Precision Medicine Study Protocol on the Heterogeneity of Taiwanese Breast Cancer Patients

References

• Dai X , LiT, BaiZet al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am. J. Cancer Res.5(10), 2929–2943 (2015).
   PubMed Web of Science ®Google Scholar
• Kuo CN , LiaoYM, KuoLNet al. Cancers in Taiwan: practical insight from epidemiology, treatments, biomarkers, and cost. J. Formos. Med. Assoc.119(12), 1731–1741 (2019).
   PubMed Web of Science ®Google Scholar
• Liu FC , LinHT, KuoCF, SeeLCet al. Epidemiology and survival outcome of breast cancer in a nationwide study. Oncotarget.8(10), 16939–16950 (2017).
   PubMedGoogle Scholar
• Jafari SH , SaadatpourZ, SalmaninejadAet al. Breast cancer diagnosis: Imaging techniques and biochemical markers. J. Cell Physiol.233(7), 5200–5213 (2018).
   PubMed Web of Science ®Google Scholar
• Mirabelli P , IncoronatoM. Usefulness of traditional serum biomarkers for management of breast cancer patients. Biomed. Res. Int.2013, 685641 (2013).
   PubMed Web of Science ®Google Scholar
• Bhargava R , BeriwalS, DabbsDJet al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer116(6), 1431–1439 (2010).
   PubMed Web of Science ®Google Scholar
• Gown AM . Diagnostic immunohistochemistry: what can go wrong and how to prevent it. Arch. Pathol. Lab. Med.140(9), 893–898 (2016).
   PubMed Web of Science ®Google Scholar
• Mazo C , BarronS, MooneyC, GallagherWM. Multi-gene prognostic signatures and prediction of pathological complete response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer patients. Cancers (Basel)12(5) (2020).
   Web of Science ®Google Scholar
• Vallon-Christersson J , HakkinenJ, HegardtCet al. Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series. Sci. Rep.9(1), 12184 (2019).
   PubMedGoogle Scholar
• Neumann MHD , BenderS, KrahnT, SchlangeT. ctDNA and CTCs in liquid biopsy – current status and where we need to progress. Comput. Struct. Biotechnol. J.16, 190–195 (2018).
   PubMed Web of Science ®Google Scholar
• Dawson SJ , TsuiDW, MurtazaMet al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med.368(13), 1199–1209 (2013).
   PubMed Web of Science ®Google Scholar
• Beaver JA , JelovacD, BalukrishnaSet al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin. Cancer Res.20(10), 2643–2650 (2014).
   PubMed Web of Science ®Google Scholar
• Oshiro C , KagaraN, NaoiYet al. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients. Breast Cancer Res. Treat.150(2), 299–307 (2015).
   PubMed Web of Science ®Google Scholar
• Kittaneh M , MonteroAJ, GluckS. Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer5, 61–70 (2013).
   PubMedGoogle Scholar
• Shen YC , ChangCJ, HsuC, ChengCC, ChiuCF, ChengAL. Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: implications from age-period-cohort analysis. Cancer Epidemiol. Biomarkers Prev.14(8), 1986–1990 (2005).
   PubMed Web of Science ®Google Scholar
• Leong SP , ShenZZ, LiuTJet al. Is breast cancer the same disease in Asian and Western countries? World J. Surg. 34(10), 2308–2324 (2010).
   PubMed Web of Science ®Google Scholar
• Kan Z , DingY, KimJet al. Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. Nat. Commun.9(1), 1725 (2018).
   PubMedGoogle Scholar
• Pan JW , ZabidiMMA, NgPSet al. The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences. Nat Commun.11(1), 6433 (2020).
   PubMed Web of Science ®Google Scholar
• Basu A , RamamoorthiG, JiaYet al. Immunotherapy in breast cancer: current status and future directions. Adv. Cancer Res.143, 295–349 (2019).
   PubMed Web of Science ®Google Scholar
• Gaynor N , CrownJ, CollinsDM. Immune checkpoint inhibitors: key trials and an emerging role in breast cancer. Semin. Cancer Biol.doi:10.1016/j.semcancer.2020.06.016 (2020) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Mina LA , LimS, BahadurSW, FirozAT. Immunotherapy for the treatment of breast cancer: emerging new data. Breast Cancer (Dove Med Press)11, 321–328 (2019).
   PubMed Web of Science ®Google Scholar
• Binns C , LowWY, LeeMK. Breast cancer: an increasing public health problem in the Asia Pacific region. Asia Pac. J. Public Health25(5), 364–367 (2013).
   PubMed Web of Science ®Google Scholar
• Youlden DR , CrambSM, YipCH, BaadePD. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol. Med.11(2), 101–115 (2014).
   PubMedGoogle Scholar
• Ghoncheh M , MomenimovahedZ, SalehiniyaH. Epidemiology, incidence and mortality of breast cancer in Asia. Asian Pac. J. Cancer Prev.17(S3), 47–52 (2016).
   PubMedGoogle Scholar
• Ji P , GongY, JinML, HuXet al. The burden and trends of breast cancer from 1990 to 2017 at the global, regional, and national levels: results from the global burden of disease study 2017. Front. Oncol.10, 650 (2020).
   PubMed Web of Science ®Google Scholar
• Schwartz LH , LitiereS, DeVries Eet al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur. J. Cancer62, 132–137 (2016).
   PubMed Web of Science ®Google Scholar
• Schwartz LH , SeymourL, LitiereSet al. RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. Eur. J. Cancer62, 138–145 (2016).
   PubMed Web of Science ®Google Scholar
• Gourgou-Bourgade S , CameronD, PoortmansPet al. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Ann Oncol.26(12), 2505–2506 (2015).
   PubMed Web of Science ®Google Scholar
• Qu X , YeungC, ColemanIet al. Comparison of four next generation sequencing platforms for fusion detection: Oncomine by ThermoFisher, AmpliSeq by illumina, FusionPlex by ArcherDX, and QIAseq by QIAGEN. Cancer Genet.243, 11–18 (2020).
   PubMed Web of Science ®Google Scholar
• Dehghani M , RosenblattKP, LiL, RakhadeM, AmatoRJ. Validation and clinical applications of a comprehensive next generation sequencing system for molecular characterization of solid cancer tissues. Front. Mol. Biosci.6, 82 (2019).
   PubMed Web of Science ®Google Scholar
• Nteliopoulos G , PageK, HillsAet al. Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients. Breast Cancer Res, Treat.doi:10.1007/s10549-021-06220-9 (2021) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Looney TJ , Topacio-HallD, LowmanGet al. TCR convergence in individuals treated with immune checkpoint inhibition for cancer. Front. Immunol.10, 2985 (2019).
   PubMed Web of Science ®Google Scholar
• Duffy MJ , HarbeckN, NapMet al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur. J. Cancer.75, 284–298 (2017).
   PubMed Web of Science ®Google Scholar
• Wan JCM , MassieC, Garcia-CorbachoJet al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer.17(4), 223–238 (2017).
   PubMed Web of Science ®Google Scholar
• Fribbens C , O'LearyB, KilburnLet al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J. Clin. Oncol.34(25), 2961–2968 (2016).
   PubMed Web of Science ®Google Scholar
• Baselga J , ImSA, IwataHet al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol.18(7), 904–916 (2017).
   PubMed Web of Science ®Google Scholar
• Oliveira KCS , RamosIB, SilvaJMCet al. Current perspectives on circulating tumor DNA, precision medicine, and personalized clinical management of cancer. Mol. Cancer Res.18(4), 517–528 (2020).
   PubMed Web of Science ®Google Scholar
• Kruger S , IlmerM, KoboldSet al. Advances in cancer immunotherapy 2019 – latest trends. J. Exp. Clin. Cancer Res.38(1), 268 (2019).
   PubMed Web of Science ®Google Scholar
• Topalian SL , DrakeCG, PardollDM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell.27(4), 450–461 (2015).
   PubMed Web of Science ®Google Scholar
• Garcia-Aranda M , RedondoM. Immunotherapy: a challenge of breast cancer treatment. Cancers (Basel)11(12), 1822 (2019).
   PubMed Web of Science ®Google Scholar
• Ayoub NM , Al-ShamiKM, YaghanRJ. Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. Breast Cancer (Dove Med Press)11, 53–69 (2019).
   PubMed Web of Science ®Google Scholar
• Garcia-Teijido P , CabalML, FernandezIP, PerezYF. Tumor-Infiltrating lymphocytes in triple negative breast cancer: the future of immune targeting. Clin. Med. Insights Oncol.10(Suppl. 1), 31–39 (2016).
   PubMedGoogle Scholar
• Loi S , MichielsS, SalgadoRet al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann. Oncol.25(8), 1544–1550 (2014).
   PubMed Web of Science ®Google Scholar
• Venturi V , ThomasPG. The expanding role of systems immunology in decoding the T cell receptor repertoire. Curr. Opin. Syst. Biol.12, 37–45 (2018).
   PubMedGoogle Scholar
• Bradley P , ThomasPG. Using T cell receptor repertoires to understand the principles of adaptive immune recognition. Annu. Rev. Immunol.37, 547–570 (2019).
   PubMed Web of Science ®Google Scholar
• Page DB , YuanJ, RedmondDet al. Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after Immunotherapy. Cancer Immunol. Res.4(10), 835–844 (2016).
   PubMed Web of Science ®Google Scholar